Krudsood Srivicha, Tangpukdee Noppadon, Muangnoicharoen Sant, Thanachartwet Vipa, Luplertlop Nutthanej, Srivilairit Siripan, Wilairatana Polrat, Kano Shigeyuki, Ringwald Pascal, Looareesuwan Sornchai
Faculty of Tropical Medicine, Mahidol University, Bangkok, 10400, Thailand.
Korean J Parasitol. 2007 Jun;45(2):111-4. doi: 10.3347/kjp.2007.45.2.111.
Chloroquine remains the drug of choice for the treatment of vivax malaria in Thailand. Mixed infections of falciparum and vivax malaria are also common in South-East Asia. Laboratory confirmation of malaria species is not generally available. This study aimed to find alternative regimens for treating both malaria species by using falciparum antimalarial drugs. From June 2004 to May 2005, 98 patients with Plasmodium vivax were randomly treated with either artemether-lumefantrine (n = 47) or chloroquine (n = 51). Both treatments were followed by 15 mg of primaquine over 14 days. Adverse events and clinical and parasitological outcomes were recorded and revealed similar in both groups. The cure rate was 97.4% for the artemether-lumefantrine treated group and 100% for the chloroquine treated group. We concluded that the combination of artemether-lumefantrine and primaquine was well tolerated, as effective as chloroquine and primaquine, and can be an alternative regimen for treatment of vivax malaria especially in the event that a mixed infection of falciparum and vivax malaria could not be ruled out.
氯喹仍然是泰国治疗间日疟的首选药物。恶性疟和间日疟的混合感染在东南亚也很常见。疟疾种类的实验室确诊通常无法实现。本研究旨在通过使用抗恶性疟药物寻找治疗这两种疟疾病种的替代方案。2004年6月至2005年5月，98例间日疟原虫患者被随机分为两组，分别接受蒿甲醚-本芴醇治疗（n = 47）或氯喹治疗（n = 51）。两种治疗均在14天内给予15毫克伯氨喹。记录不良事件以及临床和寄生虫学结果，结果显示两组相似。蒿甲醚-本芴醇治疗组的治愈率为97.4%，氯喹治疗组为100%。我们得出结论，蒿甲醚-本芴醇与伯氨喹联合使用耐受性良好，与氯喹和伯氨喹一样有效，尤其在无法排除恶性疟和间日疟混合感染的情况下，可作为治疗间日疟的替代方案。
